New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
09:17 EDTOPKOPKO: Neovasc reports successful first human implant of Tiara valve
OPKO Health reported that Neovasc, a Vancouver-based company in which OPKO has made a strategic investment, reported that a first-in-human implantation of its Tiara transcatheter mitral valve was successfully performed on January 30 by physicians at St. Paul’s Hospital in Vancouver, BC. The transapical procedure resulted in the elimination of mitral regurgitation and significantly improved heart function in the patient, without the need for cardiac bypass support and with no procedural complications.
News For OPK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
07:16 EDTOPKOPKO Health score test shows positive prostate cancer risk identification result
Opko Health (OPK) announced the publication of a study showing that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore Test accurately identifies risk for aggressive prostate cancer prior to prostate biopsy. The Prostate Testing for Cancer and Treatment study is a prospective randomized controlled trial conducted in the U.K. for the purpose of evaluating the cost effectiveness of conventional treatments in PSA-detected, clinically localized prostate cancer. The study showed that the four kallikrein panel enhanced aggressive prostate cancer detection compared with PSA and age alone.
April 21, 2015
10:59 EDTOPKOPKO Health announces publication of ProtecT study
OPKO Health announced the online publication of a study entitled “Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study” in the Journal of the National Cancer Institute. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore Test accurately identifies risk for aggressive prostate cancer prior to prostate biopsy. The Prostate Testing for Cancer and Treatment, or ProtecT, study is a prospective randomized controlled trial conducted in the United Kingdom for the purpose of evaluating the cost effectiveness of conventional treatments in PSA-detected, clinically localized prostate cancer. Of the 82,428 men recruited for the trial, a total of 6129 men with elevated PSA who underwent prostate biopsy and provided an adequate blood sample were tested for the four kallikreins and their 4Kscore result was determined. The study showed that the four kallikrein panel enhanced aggressive prostate cancer detection compared with PSA and age alone. The area under the curve for the 4K model was 0.820 while the PSA model was 0.738 for high-grade cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use